Ziltivekimab

Bagsværd, Denmark 3 February 2026 - Financial report for the period 1 January 2025 to 31 December 2025 Operating profit decreased by 1% in Danish kroner and increased by 6% at constant exchange rates (CER) to DKK 127.7 billion. Had Novo Nordisk not incurred costs related to the company-wide transformation of around DKK 8 billion, operating profit would have increased by 6% in Danish kroner and 13% at CER. Sales in US Operations increased by 3% in Danish kroner (8% at CER) and were positively impacted by gross-to-net sales adjustments. Sales in International Operations increased by 10% in Danish kroner (14% at CER). Sales within Obesity and Diabetes care increased by 7% in Danish kroner to DKK 289.5 billion (10% at CER), mainly driven by Obesity care growth of 26% in Danish kroner (31% at CER) and GLP-1 diabetes sales growing 2% in Danish kroner (6% at CER). Rare disease sales increased by 5% in Danish kroner (9% at CER). On 22 December, the US FDA approved the first oral GLP-1 in obesity, once-daily oral semaglutide 25 mg, under the brand name of Wegovy ® pill. Wegovy ® pill was launched on 5 January 2026, and as of 23 January, total weekly prescriptions amounted to around 50,000. Prescription uptake is mainly driven by the 1.5 mg starter dose in the self-pay channel. Key R&D developments in the quarter include the phase 2 trial with zenagamtide (previously amycretin) showing significant weight loss and HbA 1c reduction in type 2 diabetes, and the phase 3 trial REIMAGINE 2 with CagriSema, also in diabetes, was successfully completed. Within obesity, Novo Nordisk has submitted semaglutide 7.2 mg and the next-generation asset CagriSema to the US FDA. Adjusted sales growth for 2026, which excludes revenue from the reversal of 340B provisions, is expected to be -5 to -13% at CER. Adjusted sales growth reported in Danish kroner is expected to be 3 percentage points lower than at CER. The sales outlook is impacted by lower realised prices, including impacts related to the "Most Favoured Nations" agreement in the US and the patent expiry of the semaglutide molecule in certain IO markets, as well as competition. The global GLP-1 market is expected to continue to expand with Novo Nordisk introducing new treatments, such as Wegovy ® pill and higher doses of Wegovy ® , enabling Novo Nordisk to continue to increase patient reach and expand volumes. Adjusted operating profit growth is expected to be -5 to -13% at CER. Adjusted operating profit growth reported in Danish kroner is expected to be 5 percentage points lower than at CER. Sales and operating profit for 2026 will be positively impacted by a reversal of sales rebate provisions of USD 4.2 billion related to the 340B Drug Pricing Program in the US. At the Annual General Meeting on 26 March 2026, the Board of Directors will propose a final dividend of DKK 7.95 per share for 2025, taking the expected total dividend for 2025 to 11.70. The Board of Directors has decided to initiate a new share repurchase programme of up to DKK 15 billion. PROFIT AND LOSS 2025 2024 Growth as reported Growth at CER* DKK million Net sales 309,064 290,403 6% 10% Operating profit 127,658 128,339 (1%) 6% Net profit 102,434 100,988 1% N/A Diluted earnings per share (in DKK) 23.03 22.63 2% N/A * CER: Constant exchange rates (average 2024). "Novo Nordisk delivered 10% sales growth in constant exchange rates and reached nearly 46 million people with our innovative treatments, despite 2025 being a challenging year for the company. In 2026, Novo Nordisk will face pricing headwinds in an increasingly competitive market. However, we are very encouraged by the promising early uptake from the US launch of Wegovy ® pill, and we remain confident in our ability to drive volume growth over the coming years. Also for this year, we look forward to regulatory decisions for next-generation treatments, such as Mim8 within haemophilia and CagriSema within obesity, as well as a number of exciting R&D read-outs, including phase 3 read-outs for etavopivat and ziltivekimab," said Mike Doustdar, president and CEO. On 3 February 2026 at 13.00 CET, corresponding to 07.00 am EST, an earnings call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under 'Investors' (the contents of the company's website do not form a part of this Form 6-K). A bout Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, X, LinkedIn and YouTube. Contacts for further information Media: Ambre James-Brown +45 3079 9289 globalmedia@novonordisk.com Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com Investors: Michael Novod +45 3075 6050 nvno@novonordisk.com Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com Max Ung +45 3077 6414 mxun@novonordisk.com Sina Meyer +45 3079 6656 azey@novonordisk.com Christoffer Sho Togo Tullin +45 3079 1471 cftu@novonordisk.com Alex Bruce +45 3444 2613 axeu@novonordisk.com Frederik Taylor Pitter (US) +1 609 613 0568 fptr@novonordisk.com Company announcement No 4 / 2026 Attachment CA260203-Q4-2025

Ventyx Biosciences’ Phase 2 data showed a significant reduction in cardiovascular risks in patients with obesity through NLRP3 inhibition, a closely-watched target in neurologic and cardiometabolic drug development. After the readout was announced on Wednesday, the biotech’s stock $VTYX was up more than 85% on Thursday morning. That said, the future of VTX3232 could hinge on the ambitions of Sanofi, which paid $27 million in September 2024 to snag the rights to first negotiation for the once-daily oral NLRP3 inhibitor. Sanofi has acted on similar rights, having bought Vigil Neuroscience earlier this year after getting the negotiation rights to the biotech’s Alzheimer’s disease drug in 2024. “This is the first time we’re publicly disclosing this data, so [Sanofi] has not had a chance to see it. I’m hoping some of them have seen it today,” Ventyx CEO Raju Mohan said Wednesday during an analyst call. It’s unclear how long Sanofi gets to “review the results and determine if they have an interest in the molecule,” according to a Stifel note. A Sanofi spokesperson didn’t respond to a request for comment. The company is scheduled to report its third-quarter results on Friday. “Ultimately, NLRP3 could be a high-value target for big pharma,” Jefferies analysts wrote in a note. NLRP3 inhibitors tamp down on inflammation to lower cardiovascular risks, but they may also have the potential to treat neurological disorders. VTX3232 has completed a Phase 2 biomarker trial in patients with early forms of Parkinson’s disease. The target has attracted the interest of both drug giants and small biotechs working in cardiometabolic and neurologic R&D. That includes Novo Nordisk-partnered Ventus Therapeutics , Tenvie and NodThera , which is backed by Sanofi Ventures. Roche is also working on a Phase 1b oral candidate called selnoflast from its acquisition of Inflazome in 2020 for $448 million upfront. In the Phase 2 trial results, Ventyx said VTX3232 led to “significant reductions” in cardiovascular disease threats. The trial tested the experimental medicine alone and in combination with Novo Nordisk’s GLP-1 semaglutide. The primary endpoint of the trial was safety and tolerability. Ventyx said rates of adverse events for patients on its drug were “comparable to placebo.” On the key secondary endpoint, looking at inflammation, patients taking VTX3232 had a 64% reduction in high-sensitivity C-reactive protein (hsCRP) in the “full analysis set” at week 12 relative to baseline. There was a 3% increase in that measure in the placebo group. The p-value came in at p<0.0001. Meanwhile, the drug also led to statistically significant drops in lipoprotein(a) and liver inflammation, and it helped move interleukin-6 levels below the threshold for cardiovascular risk, according to Ventyx. The drug did not lead to weight loss, either as a single agent or in combination with semaglutide. The data are “now showing conclusively that NLRP3 inhibition has no effect in humans in promoting weight loss,” Mohan said on the call. Stifel analysts said it was “puzzling” that there was no effect on weight, given the signals in mouse models. But “the impact on biomarkers could support a path forward” for the drug in reducing cardiovascular risks, they wrote. Novartis bet $1.4 billion last month to get an anti-IL-6 drug via its acquisition of Tourmaline Bio , and Novo is also developing an IL-6 called ziltivekimab, which is in Phase 3 trials . “The potential for an ‘oral IL-6’ clearly has wide-ranging potential across a range of CV diseases with ongoing outcomes studies expected over the 2026/27 timeframe for Novo’s ziltivekimab, which represents a meaningful datapoint for the space,” the Stifel analysts wrote.